Alnylam Pharmaceuticals Inc. (ALNY) Downgraded to Market Perform at Leerink Swann
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) was downgraded by analysts at Leerink Swann to a “market perform” rating in a research report issued on Thursday.
Several other equities research analysts also recently weighed in on the company. Credit Suisse Group AG set a $145.00 price target on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, September 30th. FBR & Co reissued an “outperform” rating and issued a $180.00 price target on shares of Alnylam Pharmaceuticals in a report on Sunday, July 17th. Jefferies Group reissued a “buy” rating and issued a $80.00 price target (down previously from $119.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, June 8th. Zacks Investment Research downgraded Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, July 25th. Finally, Morgan Stanley assumed coverage on Alnylam Pharmaceuticals in a report on Tuesday, August 2nd. They issued an “overweight” rating and a $93.00 price target for the company. Five equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Alnylam Pharmaceuticals presently has an average rating of “Buy” and an average target price of $106.13.
Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 70.30 on Thursday. Alnylam Pharmaceuticals has a 52 week low of $49.96 and a 52 week high of $110.75. The company’s 50 day moving average price is $72.86 and its 200-day moving average price is $66.46. The company’s market capitalization is $6.03 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, topping the consensus estimate of ($1.24) by $0.19. The business earned $8.70 million during the quarter, compared to the consensus estimate of $8.09 million. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The company’s quarterly revenue was up .2% on a year-over-year basis. During the same quarter last year, the company earned ($0.85) earnings per share. Equities research analysts expect that Alnylam Pharmaceuticals will post ($4.64) earnings per share for the current year.
In other news, CEO John Maraganore sold 30,151 shares of the business’s stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total value of $1,950,468.19. Following the completion of the sale, the chief executive officer now directly owns 148,465 shares in the company, valued at $9,604,200.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.00% of the stock is owned by insiders.
Hedge funds have recently modified their holdings of the company. Wellington Management Group LLP raised its stake in shares of Alnylam Pharmaceuticals by 12.1% in the first quarter. Wellington Management Group LLP now owns 11,945,607 shares of the biopharmaceutical company’s stock worth $749,826,000 after buying an additional 1,288,123 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 3.5% in the second quarter. Vanguard Group Inc. now owns 5,385,509 shares of the biopharmaceutical company’s stock worth $298,843,000 after buying an additional 182,614 shares in the last quarter. Baillie Gifford & Co. raised its stake in shares of Alnylam Pharmaceuticals by 0.3% in the second quarter. Baillie Gifford & Co. now owns 3,390,252 shares of the biopharmaceutical company’s stock worth $188,125,000 after buying an additional 10,317 shares in the last quarter. Dodge & Cox purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $139,650,000. Finally, State Street Corp raised its stake in shares of Alnylam Pharmaceuticals by 13.4% in the second quarter. State Street Corp now owns 2,195,504 shares of the biopharmaceutical company’s stock worth $121,832,000 after buying an additional 258,984 shares in the last quarter. 85.96% of the stock is currently owned by hedge funds and other institutional investors.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.